581 results match your criteria: "Kanagawa Cardiovascular and Respiratory Center.[Affiliation]"

Article Synopsis
  • A 73-year-old man with a persistent cough underwent chest CT scans, revealing lung abnormalities and elevated blood markers for inflammation.
  • After conducting an antigen avoidance test, both his lung imaging and blood results showed improvement, leading to a diagnosis of hypersensitivity pneumonitis (HP).
  • The source of his HP was traced to mold found on decaying walls in his home, highlighting the need for a systematic approach to identify the triggers of this condition.
View Article and Find Full Text PDF

Objectives: Dyspnoea is a common and distressing symptom in patients with cancer. We aimed to analyse the association between dyspnoea and related factors and to estimate their causal relationship.

Methods: A cross-sectional study was conducted.

View Article and Find Full Text PDF

Background: This prospective multicenter study assessed the prevalence of myocardial injury in patients with COVID-19 using cardiac magnetic resonance imaging (CMR).

Methods And Results: We prospectively screened 505 patients with moderate to severe COVID-19 disease from 7 hospitals in Japan. Of these patients, 31 (mean [±SD] age 63.

View Article and Find Full Text PDF

Invasive mucinous adenocarcinoma (IMA) of the lung is a rare variant of adenocarcinoma characterized by abundant intracytoplasmic mucin within the tumor. Although IMA has poor sensitivity to conventional chemotherapy regimens used for non-small cell lung cancer, we observed a better response to the bevacizumab (BEV) regimen. In this retrospective study, we aimed to investigate the response to BEV-combined regimens in patients with IMA.

View Article and Find Full Text PDF

A 42-year-old woman visited our hospital with complaints of fever, muscle pain, and dyspnea one week after receiving the coronavirus disease 2019 (COVID-19) vaccine. Chest high-resolution computed tomography showed a patchy consolidation and ground-glass attenuation in the both lungs, consistent with acute interstitial pneumonia. Transbronchial lung cryobiopsy revealed organizing pneumonia with marked intra-alveolar fibrin, and pathologically diagnosed as acute fibrinous organizing pneumonia (AFOP).

View Article and Find Full Text PDF

Aim: To evaluate the clinical utility of feature tracking (FT)-derived myocardial strain in patients with non-ischaemic dilated cardiomyopathy (NIDCM).

Materials And Methods: Electronic database searches of PubMed, Web of Science Core Collection, Cochrane advanced search, and EMBASE were performed. Studies on NIDCM were divided into categories according to left ventricular ejection fraction (LVEF; <30%, 30-40%, >40%), and correlations between strains and prevalence of late gadolinium enhancement (LGE) were evaluated by weighted correlation coefficients.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the best timing and criteria for treating postoperative air leaks after lung surgery, as practices vary across hospitals.
  • Using data from a 2019 multicenter study, researchers identified 420 patients with air leaks and compared those who received treatment to those who were only monitored.
  • Key findings showed that factors like low body mass index, type of lung surgery, use of fibrin glue, and the severity of air leaks on the first postoperative day can predict the need for intervention, and that a significant number of air leaks resolved spontaneously within a week.
View Article and Find Full Text PDF

Background And Objective: Interstitial lung disease (ILD) is characterized by dyspnoea on exertion and exercise-induced hypoxaemia. High-flow nasal cannula (HFNC) therapy reduces the respiratory workload through higher gas flow and oxygen supplementation, which may affect exercise tolerance. This study aimed to examine the effects of oxygen and gas flow rates through HFNC therapy on exercise tolerance in ILD patients.

View Article and Find Full Text PDF

A fatal acute exacerbation (AE) occasionally develops during chemotherapy for small cell lung cancer (SCLC) with comorbid idiopathic pulmonary fibrosis (IPF). This study aimed to assess the safety and efficacy of carboplatin, etoposide, and nintedanib combination therapy for unresectable SCLC with comorbid IPF. The NEXT-SHIP study is a multicenter, single-arm, phase 2 trial for unresectable SCLC with IPF (Japan Registry of Clinical Trials registry number jRCTs031190119).

View Article and Find Full Text PDF

The present case involved a 78-year-old woman with repeated recurrences of allergic bronchopulmonary mycosis (ABPM) who presented to our outpatient clinic with a chief complaint of dyspnoea with respiratory failure. Computed tomography (CT) of the chest showed atelectasis of the lower lobes due to mucus plugs. Blood and biochemical tests showed a high peripheral blood eosinophil count (1330/μL) and elevated immunoglobulin E (15,041 IU/mL; normal, < 361 IU/mL).

View Article and Find Full Text PDF

Patients with lung cancer complicated by interstitial pneumonia (IP) often lose treatment options early owing to acute exacerbation of IP concerns. Carbon-ion radiotherapy (CIRT) can provide superior tumor control and low toxicity at high dose concentrations. We conducted a retrospective analysis of the efficacy and tolerability of a single-fraction CIRT using 50 Gy for IP-complicated lung cancer.

View Article and Find Full Text PDF

Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer associated with poor prognosis and resistance to conventional chemotherapy. Immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, were found to have clinical benefits in PSC in recent studies. Nevertheless, because these studies included a small number of patients owing to disease rarity, larger studies are needed to evaluate the effectiveness and safety of ICI-based therapy for PSC.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates metachronous lung cancer (arising after resection of non-small-cell lung cancer), distinguishing between second primary lung cancer (SPLC) and intrapulmonary metastasis (IPM), which is challenging to diagnose.
  • A retrospective analysis included 105 patients who had a second lung resection, revealing that most had SPLC, and the overall 5-year survival rate after surgery was 70.6%.
  • Key factors affecting poor survival rates included being over 70 years old at the second surgery, male sex, lymph node involvement, larger tumor size, and shared histology with the original cancer, although histological IPM wasn't a significant risk factor.
View Article and Find Full Text PDF
Article Synopsis
  • - The study examined the timing and effects of durvalumab therapy after concurrent chemoradiotherapy (CCRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC).
  • - Conducted as a phase II clinical trial, 47 out of 50 treated patients showed a 1-year progression-free survival (PFS) rate of 75.0%, with an objective response rate of 78.7% and a median PFS of 14.2 months.
  • - The findings suggest that starting durvalumab immediately after CCRT is both effective and safe, with similar rates of serious side effects like pneumonitis to previous studies.
View Article and Find Full Text PDF

A prospective cohort study of periostin as a serum biomarker in patients with idiopathic pulmonary fibrosis treated with nintedanib.

Sci Rep

December 2023

Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.

Article Synopsis
  • This study looked at a protein called periostin to see if it could help doctors predict how well patients with a lung disease called idiopathic pulmonary fibrosis (IPF) would do after treatment with a drug named nintedanib.
  • Researchers measured different levels of periostin in 87 patients and compared them to 43 other patients who hadn't been treated with antifibrotic drugs before.
  • They found that higher levels of periostin were linked to better chances of survival and more effectiveness of nintedanib in treating IPF, which might help doctors make better treatment plans in the future.
View Article and Find Full Text PDF
Article Synopsis
  • Biomarker testing for driver mutations in non-small cell lung cancer (NSCLC) is crucial for treatment selection, yet current practices in Japan reveal limitations.
  • The REVEAL cohort study involved data collection from 29 institutions, examining 1479 patients diagnosed with advanced or recurrent NSCLC to assess biomarker testing and treatment issues.
  • The study found that while 86.1% of patients had confirmed biomarker status, there were varying positivity rates among different gene tests, indicating challenges in effective treatment decisions based on biomarker testing.
View Article and Find Full Text PDF
Article Synopsis
  • Pulmonary fibrosis (PF) is a lung disease that makes it hard to breathe and can be life-threatening.
  • Scientists discovered that certain mice (Ifngr1Rag2) that lack a key suppressor for immune cells called ILC2 can develop PF on their own.
  • The study shows that these ILC2 cells produce a protein that makes fibroblasts (cells that help with tissue repair) create too much collagen, causing the lungs to become stiff and fibrous.
View Article and Find Full Text PDF

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease characterized by complex lung pathogenesis affecting approximately three million people worldwide. While the molecular and cellular details of the IPF mechanism is emerging, our current understanding is centered around the lung itself. On the other hand, many human diseases are the products of complex multi-organ interactions.

View Article and Find Full Text PDF
Article Synopsis
  • - The OCEAN study evaluated the effectiveness of osimertinib in treating radiation therapy-naive CNS metastasis in patients with mutation-positive non-small cell lung cancer (NSCLC), focusing on a cohort of previously untreated individuals.
  • - Results showed a brain metastasis response rate of approximately 76.9% and a median progression-free survival (PFS) of 22 months for CNS metastasis, indicating significant effectiveness of osimertinib in this patient group.
  • - The study reported manageable side effects, with less than 10% experiencing severe adverse events, suggesting osimertinib is a promising first-line treatment option for these patients.
View Article and Find Full Text PDF

Objective: The objective of this meta-analysis was to assess the clinical utility of anomalous discoveries on cardiac magnetic resonance, particularly the right ventricular extracellular volume (RV-ECV), among individuals who underwent surgical repair for Tetralogy of Fallot (rTOF).

Methods: We conducted a systematic search of electronic databases including PubMed, Web of Science Core Collection, Cochrane advanced search, and EMBASE. Our analysis involved a comparison of ECV levels between rTOF patients and controls, as well as an evaluation of the predictive value of ECV for future adverse events.

View Article and Find Full Text PDF
Article Synopsis
  • The Japanese Respiratory Society has released a new clinical practice guide for diagnosing hypersensitivity pneumonitis (HP), outlining various common types of HP found in Japan and emphasizing the importance of identifying specific antigens for effective diagnosis and treatment.
  • The guide features a comprehensive antigen questionnaire tailored to local outbreak sources and adopts diagnostic criteria based on imaging, exposure assessment, and laboratory results, while including additional notes for clarification.
  • It stresses the significance of avoiding antigens, monitoring biomarkers like KL-6 levels, and provides insights into pharmacological management strategies for treating fibrotic HP, including combination therapies.
View Article and Find Full Text PDF

Background: Idiopathic multicentric Castleman disease (iMCD) is a rare polyclonal lymphoproliferative disease often associated with pulmonary involvement. Recently, transbronchial lung cryobiopsy (TBLC) has been reported to be useful for the diagnosis of diffuse interstitial lung disease. However, there have been no reports of pathological assessment of TBLC for iMCD.

View Article and Find Full Text PDF

Risk factors of severe coronavirus disease 2019 (COVID-19) have been previously reported; however, histological risk factors have not been defined thus far. The aim of this study was to clarify subclinical hidden interstitial lung disease (ILD) as a risk factor of severe pneumonia associated with COVID-19. We carefully examined autopsied lungs and chest computed tomography scanning (CT) images from patients with COVID-19 for interstitial lesions and then analyzed their relationship with disease severity.

View Article and Find Full Text PDF
Article Synopsis
  • The phase III IMPACT study evaluated the effectiveness of adjuvant gefitinib compared to cisplatin plus vinorelbine (cis/vin) for patients with completely resected EGFR-mutated non-small cell lung cancer (NSCLC).
  • Although the study didn't meet its main goal of improving disease-free survival (DFS), researchers focused on identifying molecular predictors of gefitinib's effectiveness among 202 patients analyzed for cancer-related gene mutations.
  • Key findings revealed that NOTCH1 co-mutations indicated a poorer overall survival in the gefitinib group, while CREBBP co-mutations suggested better outcomes in terms of DFS and overall survival for the cis/vin group.
View Article and Find Full Text PDF